Lymphoid clinical trials

Explore recruiting lymphoid clinical trials.

Recruiting lymphoid studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoid trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in patients with CD19+ acute lymphoid leukemia resistant or refractory to therapy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I / II clinical trial, randomized, exploratory and prospective to evaluate the safety and efficacy of the transfusion of autologous TREG cells obtained from thymic tissue in the prevention of rejection in heart transplanted children

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

TAYLOR : A multicentric phase II trial evaluating volrustomig (MEDI5752) in patients with mature tertiary lymphoid structures solid tumors.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers

Spain, Denmark, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Lymphoid trials by city

Lymphoid in Toronto Lymphoid in Vancouver Lymphoid in Montreal Lymphoid in Calgary Lymphoid in Edmonton Lymphoid in Ottawa Lymphoid in Winnipeg Lymphoid in Quebec City Lymphoid in Hamilton Lymphoid in Kitchener Lymphoid in London Lymphoid in Halifax Lymphoid in New York Lymphoid in Los Angeles Lymphoid in Chicago Lymphoid in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease